Abstract. The receptor activator for nuclear factor κB ligand/ receptor activator for nuclear factor κB (RANKL/RANK) pathway is critical for RANK-expressing cancer cells to home to bones, and c-Src is critical for cancer progression. The objective of this study was to explore the effect of c-Src in the RANKL/RANK pathway and migration activity in human breast cancer cells. Breast cancer cell lines MCF-7, MDA-MB-231 and BT-474 were obtained and cultured. Flow cytometry was used to examine RANK expression. The results showed that RANK was expressed in breast cancer cell lines MCF-7, MDA-MB-231 and BT-474, and soluble RANKL (sRANKL)-triggered migration of breast cancer cells by activating ERK1/2, Akt and c-Src. The sRANKL-induced migration was blocked with RANKL inhibitor osteoprotegerin (OPG), MEK inhibitor PD98059, PI3K inhibitor LY294002 and Src inhibitor PP2. Inhibition of c-Src function with PP2 blocked the activation of Akt and ERK1/2, resulting in the inhibition of RANKL-induced migration. In conclusion, RANKL was found to increase the migration of breast cancer cells by activating the c-Src-Akt and c-Src-ERK signaling pathways.
Introduction
Breast cancer is the most common cancer among women, and is second only to lung cancer as the leading cause of cancer mortality (1) . Although early stage breast cancer is not life threatening, development of metastatic breast cancer is responsible for the majority of cancer-related mortality. Advanced breast cancer commonly spreads to the bones, lungs, liver or brain, with bone being the most common site of breast cancer metastasis. Almost all patients with advanced breast cancer finally develop bone metastasis and suffer from serious bone metastases-associated complications. Therefore, understanding the mechanisms that facilitate bone metastasis is of great importance.
For the past decade, chemokine pathways, such as SDF-1/ CXCR4 and CCL21/CCR7, were thought to play a significant role in breast cancer distant metastasis (2,3). However, it was shown that inhibition of these pathways in vivo only partially blocks metastatic behavior (2) (3) (4) , indicating that other factors exist that regulate the metastasis of breast cancer cells. Receptor activator of NF-κB ligand (RANKL) is a member of the tumor necrosis factor family of cytokines and its receptor, receptor activator of NF-κB (RANK), is primarily expressed on osteoclasts. Previous studies showed that RANKL binds to RANK or the decoy receptor osteoprotegrein (OPG) (5) to modulate osteoclast differentiation, activation and survival (6) (7) (8) (9) (10) (11) . RANK is reportedly expressed in certain cancer cells, and the RANKL/RANK pathway induces the migration of prostate, renal, lung and human breast cancer cells, T47D (4, (12) (13) (14) (15) . Furthermore, the RANKL/RANK pathway has been shown to trigger the bone-specific migration of RANK-expressing mouse malignant melanoma and human prostate cancer cells (4, 13) . However, the RANKL-mediated signaling pathways in breast cancer cells are not well understood.
The non-receptor tyrosine kinase c-Src, a significant molecule in cell migration, adhesion and osteoclast-mediated bone resorption (16) (17) (18) , is also over-expressed and activated in a large number of human malignancies, and the correlation between c-Src activation and cancer progression appears to be significant (18) . c-Src is reportedly involved in RANKLinduced prostate cancer cell migration (19) and promotes lung and latent breast cancer bone metastasis (20, 21) . However, the effect of c-Src on the RANKL/RANK pathway and migration activity in human breast cancer cells remains unknown.
In this study, we described a phenomenon whereby the RANKL and RANK interaction increased the migration of three representative human breast cancer cell lines, MCF-7 (ER/PR RANK expression analysis. Surface RANK expression was determined by flow cytometry following incubation with 25 µg per 1x10 6 cells mouse anti-RANK antibody (R&D) or isotype control (R&D) followed by FITC-conjugated antimouse secondary antibody. Fluorescence was assessed using a FAScan sorter (BD Biosciences, NJ, USA).
Western blotting. To prepare total cell lysates, cell pellets were washed twice with ice-cold phosphate-buffered saline (PBS) and solubilized in 1% Triton lysis buffer [1% Triton X-100, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride and 2 µg/ml aprotinin] on ice. Cell lysates were centrifuged at 12,000 x g for 30 min at 4˚C and the supernatants were separated. Proteins were eluted by heat treatment at 100˚C for 5 min with 3X sampling buffer. Total proteins (30-50 µg) were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electronically transferred to nitrocellulose membranes. After blocking with 5% skimmed milk in 10 mM Tris, pH 7.4, 150 mM NaCl and 0.1% Tween 20 (TBST), the blots were probed with the indicated primary antibodies at 4˚C overnight, followed by the horseradish peroxidase-conjugated specific goat anti-mouse or goat anti-rabbit secondary antibody, as indicated for 30 min at room temperature. Finally, proteins were detected using an enhanced chemiluminescence reagent (SuperSignal Western Pico Chemilunescent Substrate; Pierce, IL, USA) and visualized with the Electrophoresis Gel Imaging Analysis System (DNR Bio-Imaging Systems, Israel).
Transwell migration assay. Cells were washed twice in culture medium with 0.1% bovine serum albumin. A 24-well chemotaxis chamber (8-µm pore size; Corning; NY, USA) was used for this experiment. Prior to performing the migration assay, cells were pretreated with different concentrations of inhibitors or the appropriate solvent control [dimethyl sulfoxide (DMSO)] for 60 min. A volume of 200 µl (2x10 5 cells/ml) from each sample was loaded onto the upper well. The medium (0.5 ml) containing sRANKL, with or without the respective inhibitors or DMSO, was added to the bottom well. The plates were incubated for 16 h at 37˚C. Following incubation, the porous inserts were carefully removed and the cells on the lower surface of the membrane were stained and counted in at least five different fields. The results were expressed as the percentage of migrated cells as compared to the control (untreated) cells. Each experiment was performed three times and in triplicate.
Statistical analysis. Experimental data are expressed as the mean ± standard deviation. The significance of the difference between the groups was assessed by the Student's two-tailed t-test, and P<0.05 was considered significant in all statistical analyses. The mean values were calculated from at least three independent experiments. Statistical analyses were carried out using the statistical package software (SPSS for Windows, Version16.0; IBM, NY, USA). (22, 23) were selected to detect RANK expression. The result showed that all three cell lines expressed RANK on the cell surface (Fig. 1) .
Results

Breast cancer cells expressed RANK on their cell surface.
RANKL-and RANK interaction-directed migration of breast cancer cells.
Stimulation of the MCF-7 cells by sRANKL at a concentration of 2 µg/ml significantly induced increased migration. Pretreatment of cells with OPG reduced RANKLinduced cell migration ( Fig. 2A) . Furthermore, we confirmed that RANKL has no mitogenic effect on MCF-7 cells (data not shown). Therefore, the increased number of cells traversing the filter was due to migration.
Similarly, RANKL also increased the migration of MDA-MB-231 and BT-474 cells, and RANKL-induced cell migration was blocked with OPG (Fig. 2B) . Therefore, the RANKL and RANK interaction plays a significant role in the migration of human breast cancer cells.
ERK and Akt were involved in RANKL-induced breast cancer cell migration.
The downstream signaling of RANKL/ RANK in MCF-7 cells was examined. Since the Akt and ERK pathways were closely correlated with cell invasion and migration (13, 14, (24) (25) (26) , the effect of ERK and Akt in the RANKL/ RANK pathway was evaluated. The results showed that sRANKL promoted the activation of ERK and Akt in MCF-7 cells (Fig. 3A) . The sRANKL-induced migration was partially blocked with the MEK inhibitor PD98059 (25 µM) and the PI3K inhibitor LY294002 (50 µM) (Fig. 3B) .
These results suggested that the ERK and Akt pathways were involved in RANKL-induced breast cancer cell migration.
c-Src mediated, RANKL-induced breast cancer cell migration through activation of the ERK and Akt pathways.
The effect of c-Src in the RANKL/RANK pathway and migration activity in MCF-7 cells was evalutated. Rapid activation of c-Src (Fig. 4A ) in MCF-7 cells was observed following treatment with sRANKL for 5 min. In addition, PP2 (10 µM), a type of Src family kinase inhibitor, markedly inhibited sRANKL-induced MCF-7 cell migration (Fig. 4B) , accompanied with the inhibition of the activation of ERK and Akt (Fig. 4C) .
Taken together, these results suggest that c-Src-mediated RANKL-induced breast cancer cell migration occurs through activation of the ERK and Akt pathways.
Discussion
The RANKL/RANK pathway has emerged as the key pathway in the regulation of osteoclasts and lymphocyte proliferation and survival. RANKL interacts with RANK and, in turn, recruits tumor necrosis factor receptor-associated factors (TRAFs) (27) , leading to the activation of NF-κB, c-Jun N-terminal kinase (JNK), p38, ERK and Akt (28) (29) (30) . Recent studies (4, (12) (13) (14) (15) have shown that RANK is also expressed on the surface of certain cancer cells and that RANKL functions as a chemokine and directs RANK-expressing cancer cells to preferentially migrate into bone, which is the crucial and initial step for bone metastasis. However, the manner in which this cytokine is involved in tumor metastasis remains to be elucidated.
Previous studies regarding RANKL/RANK signal pathways have mainly focused on melanoma, lung and prostate cancer cells (4, 13, 14) . In the present study, three representative cell line models for different protein subtypes of breast cancer, MCF-7 (ER/PR 
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expressed in all three types of breast cancer cells. Moreover, whereas RANKL promoted the migration of breast cancer cells, OPG was able to block the enhanced migration induced by RANKL.
Findings of previous studies have shown that AKT and ERK1/2 were closely correlated with cell migration (13, 14, (24) (25) (26) . In mouse B16F10 melanoma cells, pretreatment with the inhibitor of PI3K, PKC, PLC or MEK1/2 suppressed .01 indicate significant difference compared with the control. (C) Following pretreatment with or without PP2 for 1 h, MCF-7 cells were incubated with sRANKL for indicated time intervals, and p-Src/c-Src, pAkt/Akt, pERK/ERK1/2 and β-actin were examined by Western blot analysis. RANKL, receptor activator for nuclear factor κB ligand; sRANKL, soluble receptor activator for nuclear factor κB ligand.
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RANKL-induced migration (4) . In the present study, AKT and ERK1/2 were phosphorylated following RANKL stimulation; although RANKL does not directly affect their proliferation or survival. The result was in accordance with the study by Jones et al in T47D breast cancer cells (4) . However, in prostate cancer cell lines, ERK1/2, but not Akt, was involved in RANKL-induced migration (13, 19) . Non-receptor tyrosine kinase c-Src was reported to selectively promote bone metastasis (20, 21) . In the present study, c-Src was involved in RANKL-induced breast cancer cell migration. In addition, PP2, the inhibitor of c-Src, inhibited the activation of ERK1/2 and Akt, suggesting an essential role for c-Src and downstream ERK and Akt in breast cancer cell migration. These results differ from the RANKL/RANK pathway in prostate cancer cells, in which c-Src promoted the activation of ERK1/2 but not AKT (19) . Therefore, RANKL/ RANK signaling may vary in different tumor cell types. To the best of our knowledge, this is the first study to show that c-Src may be a key downstream mediator of RANKL-induced migration in breast cancer cells.
A number of studies have examined and confirmed the link between the RANK/RANKL pathway and propensity to metastasize to the bone (4, 12, 31) . Recently, clinical trials with a fully human anti-RANKL antibody, denosumab, have been initiated in patients with prostate and breast cancer bone metastases with promising results (32, 33) . This antibody had been fast tracked by the US FDA for treatment and prevention of post-menopausal osteoporosis and treatment and prevention of bone loss in hormone-treated prostate and breast cancer patients (34, 35) . Furthermore, Src inhibitors, including dasatinib, saracatinib and bosutinib, are currently under clinical investigation for patients with solid tumors, as available data show activity in bone (36) (37) (38) (39) . Our results have shown the direct anti-metastasis effects of RANKL and/or c-Src inhibitors. Therefore, we suggest that the use of Src inhibitors and/or RANKL selective inhibitors may be of therapeutic benefit in breast cancer patients.
